Skip to main content
. 2016 Nov 21;129(5):565–571. doi: 10.1182/blood-2016-09-693648

Figure 2.

Figure 2.

Proposed flowchart for the treatment of patients with FLT-3-mutated AML. The final point, maintenance therapy in the post-transplant setting, remains an open question, one it is hoped will be addressed by randomized trials.